2-deoxy-d-glucose as an adjunct to standard of care in the medical management of COVID-19: a proof-of-concept and dose-ranging randomised phase II clinical trial

Overview of attention for article published in BMC Infectious Diseases, August 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 1 news outlet

twitter: 4 X users

Citations

dimensions_citation: 22 Dimensions

Readers on

mendeley: 30 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 5 X posts from 4 X users, with an upper bound of 825 followers.

@Shiva_Simha1 @AyushRajawat @theliverdr Point out specific faults in that 2DG research & show specific data from paper itself, not any random thread from any 2 penny pf!z€® p!mp. https://t.co/4XUrygI2sh

17 Aug 2023

Reply Repost Favourite

2-deoxy-D-glucose as an adjunct to standard of care in the medical management of COVID-19: a proof-of-concept and dose-ranging randomised phase II clinical trial https://t.co/J2fBpoMBsQ

08 Aug 2022

Reply Repost Favourite

2-deoxy-D-glucose as an adjunct to standard of care in the medical management of COVID-19: a proof-of-concept and dose-ranging randomised phase II clinical trial https://t.co/SQTTsY8VO6

08 Aug 2022

Reply Repost Favourite

2-deoxy-D-glucose as an adjunct to standard of care in the medical management of COVID-19: a proof-of-concept and dose-ranging randomised phase II clinical trial https://t.co/9h1GpTwG0b

08 Aug 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.